Sleep attacks in patients taking dopamine agonists: review

Sleep attacks in patients taking dopamine agonists: review.

OBJECTIVES To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. DESIGN Review of publications between July 1999 and May 2001 in which sleep attacks or narcoleptic-like attacks were discussed in patients with Parkinson's disease. RESULTS...

Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.

OBJECTIVE Hyperprolactinemia is associated with bone fragility. Traditionally attributed to prolactin-induced hypogonadism, recent studies have identified increased fracture rates independent of gonadal function. METHODS We performed a systematic review to identify studies assessing fracture risk in patients with untreated hyperprolactinemia compared to those on dopamine agonists. MEDLINE, EM...

Dopamine agonists, sleep disorders, and driving in Parkinson's disease.

Dopamine Agonists

Dopamine agonists (DA) have been used to treat symptoms of Parkinson’s disease (PD) since the late 1970s (1). These agents were initially introduced to supplement the beneficial effect and possibly reduce the incidence of longterm complications of levodopa. In the last 30 years, methodical investigations of DA have demonstrated therapeutic benefit in all stages of PD both in combination with le...

[Visual outcome in patients with macroprolactinoma treated with dopamine agonists].

BACKGROUND Dopamine agonists (DA) effectively reduce tumor size of macroprolactinomas, with the consequent improvement of eventual visual impairment. AIM To study the visual outcomes in patients with macroprolactinoma treated with DA. MATERIAL AND METHODS Retrospective cohort study which included patients with macroprolactinoma controlled at a Neuro-endocrinology and Neuro-ophthalmology Dep...